OATP1B1 Plays an Important Role in the Transport and Treatment Efficacy of Sorafenib in Hepatocellular Carcinoma
Open Access
- 26 September 2021
- journal article
- Published by Hindawi Limited in Disease Markers
- Vol. 2021, 1-13
- https://doi.org/10.1155/2021/9711179
Abstract
Background. Sorafenib is an anticancer drug used in the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. It is a substrate for the human OATP1B1. This study is aimed at assessing the role of OATP1B1 in transportation and uptake of sorafenib in hepatocellular carcinoma and how OATP1B1 affects the pharmacodynamics of sorafenib in vitro and in vivo. Methods. Sorafenib transport was measured in HepG2, HepG2-OATP1B1 ∗ 1a, HepG2-OATP1B1 ∗ 1b, HepG2-OATP1B1 ∗ 15, LO2, LO2-OATP1B1 ∗ 1a, LO2-OATP1B1 ∗ 1b, and LO2-OATP1B1 ∗ 15 cells, as well as in HepG2 cells transfected with miR-148a mimics. The viability and apoptosis rate of cells treated with sorafenib were evaluated. A liver cancer rat model was established to explore the pharmacokinetics and pharmacodynamics of sorafenib after overexpression of Oatp2. Results. Changes in expression and genetic mutations of OATP1B1 significantly affected the uptake of sorafenib in HepG2 and LO2 transgenic cells, and the uptake of sorafenib was higher in HepG2 than LO2. Genetic mutations of OATP1B1 significantly affected the cell viability and apoptosis rate of HepG2 cells after sorafenib treatment. Compared to control group, the uptake of sorafenib in miR-148a mimic-transfected HepG2 cells was decreased, and the cell viability was increased. PCN significantly increased the expression of Oatp2 and affected the pharmacokinetics of sorafenib. Vascular endothelial growth factor levels and microvascular density in tumor-adjacent tissues decreased significantly, suggesting that increased Oatp2 expression improves the treatment effect of sorafenib in a rat model of liver cancer. Conclusions. OATP1B1 plays an important role in the pharmacokinetics and pharmacodynamics of sorafenib in hepatocellular carcinoma.Keywords
Funding Information
- Department of Science and Technology of Jiangxi Province (20192BCBL23018, 20171ACB21059, 81860661, 81660620)
This publication has 14 references indexed in Scilit:
- Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in ratsBiochemical Pharmacology, 2019
- SorafenibPublished by Elsevier BV ,2019
- Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenibOncotarget, 2018
- Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1)British Journal of Clinical Pharmacology, 2017
- The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanismPharmaceutical Biology, 2017
- Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicityPharmacogenomics, 2016
- The drug–drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4Xenobiotica, 2015
- Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-GlucuronideClinical Cancer Research, 2013
- High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)Pharmacogenetics, 2004
- Genetic Polymorphisms of Human Organic Anion Transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele Frequencies in the Japanese Population and Functional AnalysisThe Journal of pharmacology and experimental therapeutics, 2002